Schwartz Carolyn E, Powell Victoria E
DeltaQuest Foundation, Inc., 31 Mitchell Road, Concord, MA, 01742, USA.
Departments of Medicine and Orthopaedic Surgery, Tufts University Medical School, Boston, MA, USA.
Health Qual Life Outcomes. 2017 Mar 9;15(1):47. doi: 10.1186/s12955-017-0614-z.
In 1993, the Performance Scales© was created to assess multi-dimensional disability in multiple sclerosis (MS). This tool has been used in a variety of settings and study designs internationally. The present work provides an overview of the history and psychometric characteristics of the Performance Scales©, reviews its use over the past two decades, and summarizes its responsiveness to subgroup differences.
A Google Scholar and Ovid search yielded 230 articles citing the Performance Scales©, of which 82 studies used the tool in empirical research. Twelve articles provided sufficient information to enable computation of effect sizes. Forest plots were used to show effect sizes for the overall summary score and by domain by patient demographics, MS disease trajectory, and treatment adherence.
The Performance Scales© evidenced sensitivity to clinically important differences by disease trajectory and age (for selected domains). In contrast, groups distinguished by patient adherence to disease-modifying therapies and ethnicity were relatively small.
The Performance Scales© has been used in a large number of studies since its development, suggesting that this psychometrically sound tool is acknowledged to be a useful tool for MS clinical research. It is recommended that future work include the entire measure, so that the whole-person impact of MS can be characterized and considered in MS outcome research.
1993年,创建了“绩效量表©”以评估多发性硬化症(MS)中的多维残疾情况。该工具已在国际上的各种环境和研究设计中使用。本研究概述了“绩效量表©”的历史和心理测量特征,回顾了其在过去二十年中的使用情况,并总结了其对亚组差异的反应性。
通过谷歌学术搜索和Ovid检索,得到230篇引用“绩效量表©”的文章,其中82项研究在实证研究中使用了该工具。12篇文章提供了足够的信息以计算效应量。森林图用于展示总体汇总分数以及按患者人口统计学、MS疾病轨迹和治疗依从性划分的各领域的效应量。
“绩效量表©”对疾病轨迹和年龄(特定领域)的临床重要差异具有敏感性。相比之下,按患者对疾病修饰疗法的依从性和种族划分的组相对较少。
“绩效量表©”自开发以来已在大量研究中使用,这表明该心理测量健全的工具被认为是MS临床研究的有用工具。建议未来的研究纳入整个测量指标,以便在MS结局研究中能够描述和考虑MS对患者整体的影响。